Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis
Keywords:
Topical Phosphodiesterase 4 Inhibitors, Mild to Moderate Atopic DermatitisAbstract
Background: The application of topical phosphodiesterase 4 (PDE4) inhibitors in the treatment of mild to moderate atopic dermatitis (AD) has emerged as a significant area of interest in dermatological research. The literature presents a comprehensive overview of the efficacy, safety, and therapeutic potential of these agents, particularly focusing on crisaborole and difamilast, which have shown promise in clinical settings.
Literature Review: The foundational work by (Li et al., 2018) highlighted the efficacy and safety of crisaborole, establishing it as a viable non-steroidal treatment option for AD. This pivotal study demonstrated the ability of crisaborole to reduce inflammation by inhibiting pro-inflammatory cytokines, a mechanism that is crucial given the chronic nature of AD and the need for effective long-term management strategies. The safety profile of crisaborole, particularly its tolerability in pediatric populations, supports its role as a preferred alternative to traditional corticosteroids, which often come with significant side effects. Further expanding the therapeutic landscape, (Sharma et al., 2018) introduced East Indian sandalwood oil as a PDE4 inhibitor, suggesting its potential as a natural treatment option for inflammatory skin diseases, including AD. This exploration of alternative therapies enriches the available treatment modalities, particularly for patients seeking non-pharmacological interventions. Conclusion: In conclusion, the literature collectively supports the therapeutic potential of topical PDE4 inhibitors in managing mild to moderate atopic dermatitis. The studies reviewed emphasize their efficacy in reducing inflammation and pruritus while maintaining a favorable safety profile, thus presenting a promising alternative to conventional treatments. However, ongoing research is essential to fully understand the long-term effects and optimize treatment strategies for diverse patient populations.
References
Li, H., Li, H., Zuo, J., Zuo, J., Tang, W., Tang, W., & Tang, W., 2018. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. [PDF]
Sharma, M., Levenson, C., C. Browning, J., M. Becker, E., Clements, I., Castella, P., & E. Cox, M., 2018. East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease. ncbi.nlm.nih.gov
Klasa, B. & Cichocka-Jarosz, E., 2020. Atopic Dermatitis – Current State of Research on Biological Treatment. ncbi.nlm.nih.gov
Bieber, T., 2021. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. ncbi.nlm.nih.gov
Saeki, H., Imamura, T., Yokota, D., & Tsubouchi, H., 2022. Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study. ncbi.nlm.nih.gov
Martín-Santiago, A., Puig, S., Arumi, D., & Jose Rebollo Laserna, F., 2022. Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. ncbi.nlm.nih.gov
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Maria Elsa, Marsela (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
